Live Breaking News & Updates on Unicefaurobindo pharma

Stay informed with the latest breaking news from Unicefaurobindo pharma on our comprehensive webpage. Get up-to-the-minute updates on local events, politics, business, entertainment, and more. Our dedicated team of journalists delivers timely and reliable news, ensuring you're always in the know. Discover firsthand accounts, expert analysis, and exclusive interviews, all in one convenient destination. Don't miss a beat — visit our webpage for real-time breaking news in Unicefaurobindo pharma and stay connected to the pulse of your community

Aurobindo Pharma signs exclusive licensing agreement with COVAXX

To develop and commercialize COVID-19 vaccine UB-612 for India and UNICEFAurobindo Pharma and COVAXX, a US-based company, have entered into an Exclusive License Agreement to develop, commercialize and manufacture UB-612, the first Multitope Peptide-based
Vaccine to fight COVID-19, for India and the United Nations Children's Fund (UNICEF) agency. COVAXX is currently conducting a Phase 1 clinical trial for the vaccine candidate.
Under the signed agreement, Aurobindo Pharma has obtained the exclusive rights to develop,
manufacture and sell COVAXX's UB-612 vaccine in India and to UNICEF, as well as non-exclusive rights in
other select emerging and developing markets. Aurobindo Pharma and COVAXX are partnering on clinical

Hyderabad , Andhra-pradesh , India , Unicefaurobindo-pharma , Aurobindo-pharma , United-nations-children-fund , Exclusive-license-agreement , Multitope-peptide-based-vaccine , United-nations-children , Capital-market , Articles , Medical-research